Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival

Glioblastoma (GBM) is the most malignant brain tumor where patients' survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet need for novel, effective therapeutic strategies for this devastating disease...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Poli, Aurélie, Wang, Jian, Domingues, Olivia, Planagumà, Jesús, Yan, Tao, Rygh, Cecilie Brekke, Skaftnesmo, Kai Ove, Thorsen, Frits, McCormack, Emmet, Hentges, François, Pedersen, Paal Henning, Zimmer, Jacques, Enger, Per Øyvind, Chekenya, Martha
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2013
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3824525/
https://ncbi.nlm.nih.gov/pubmed/24127551
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi